TNFA (TNF Pharmaceuticals) Ending Cash Position : $1.19 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is TNF Pharmaceuticals Ending Cash Position?

TNF Pharmaceuticals's Ending Cash Position for the quarter that ended in Sep. 2024 was $1.19 Mil.

TNF Pharmaceuticals's quarterly Ending Cash Position increased from Mar. 2024 ($0.23 Mil) to Jun. 2024 ($0.54 Mil) and increased from Jun. 2024 ($0.54 Mil) to Sep. 2024 ($1.19 Mil).

TNF Pharmaceuticals's annual Ending Cash Position increased from Dec. 2021 ($0.56 Mil) to Dec. 2022 ($0.75 Mil) and increased from Dec. 2022 ($0.75 Mil) to Dec. 2023 ($2.68 Mil).

TNF Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for TNF Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TNF Pharmaceuticals Ending Cash Position Chart

TNF Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

0.15

0.56

0.75

2.68

TNF Pharmaceuticals Quarterly Data
	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Ending Cash Position	Get a 7-Day Free Trial													0.30	2.68	0.23	0.54	1.19

TNF Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

TNF Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0.749	+	1.932
	=	2.68

TNF Pharmaceuticals's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0.536	+	0.656
	=	1.19

TNF Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of TNF Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

TNF Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (NAS:TNFA) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

0A8D:UK

Address

855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205

Website

https://tnfpharma.com

TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.

Executives

Paul Rivard	officer: EVP of Operations, GC	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Caroline C Williams	10 percent owner	324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Adam Kaplin	officer: Chief Scientific Officer	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Jude Uzonwanne	director	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Craig Eagle	director	POST OFFICE BOX 4590, NEW YORK NY 10163
Chapman Christopher C Jr	director, officer: President, Chief Med. Officer	C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Ian Rhodes	officer: Interim CFO	1375 KINGS HIGHWAY EAST, FAIRFIELD CT 06824
Stuart M Benson	officer: Chief Financial Officer	EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118
Hudson Bay Capital Management Lp	10 percent owner	28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Sander Gerber	10 percent owner	C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Robert C Schroeder	director	37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724
Howard Yeaton	officer: CEO, CFO	79 LLOYD ROAD, HOHOKUS NJ 07423
Tarbox Richard C Iii	director	AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Christopher C Schreiber	director	AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086